Log in to search using one of your social media accounts:

 

Testing for Hepatitis C - The Importance for People With Cancer

I know it's kind of off the topic, but you may have been hearing the news about testing for hepatitis C. The news isn't really new - what's new is that the public is finally being informed. For years physicians have known that hepatitis C is the leading cause of liver cancer - and the leading cause of liver transplants....Read Full Post
Source: About.com Lung Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

We describe seven patients treated with PD-1 inhibitors nivolumab and pembrolizumab for either metastatic melanoma or metastatic NSCLC in the setting of chronic or past HBV/HCV infection. The safety and efficacy of treatment were analysed retrospectively by examining response to treatment, alanine transaminase (ALT) trends and viral load trends. One patient showed an increase in ALT of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 severity that returned to the normal range following treatment of his HCV infection with ledipasvir 90 mg/sofosbuvir 400 mg. An additional four patients showed an i...
Source: Melanoma Research - Category: Cancer & Oncology Tags: Short Communications Source Type: research
Excerpted fromPrecision Medicine and the Reinvention of Human DiseaseDespite having the most advanced healthcare technology on the planet, life expectancy in the United States is not particularly high. Citizens from most of the European countries and the highly industrialized Asian countries enjoy longer life expectancies than the United States. According to the World Health Organization, the United States ranks 31st among nations, trailing behind Greece, Chile, and Costa Rica, and barely edging out Cuba [42]. Similar rankings are reported by the US Central Intelligence Agency [43]. These findings lead us to infer that acc...
Source: Specified Life - Category: Information Technology Tags: cancer cancer vaccines precision medicine prevention public health Source Type: blogs
ConclusionRBV‐free DAA combinations for the treatment of HCV recurrence after OLT are highly efficacious and well tolerated. Our long‐term data show that viral eradication is durable but not necessarily translated into beneficial long‐term clinical outcome.
Source: Liver International - Category: Gastroenterology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsPost‐SVR cirrhosis regression does not prevent HCC occurrence.This article is protected by copyright. All rights reserved.
Source: Liver International - Category: Gastroenterology Authors: Tags: Original Article Source Type: research
Conclusion: Our study found a significant association of airway obstruction with HIV status in smokers aged more than 40 years with previous immunodeficiency.
Source: AIDS - Category: Infectious Diseases Tags: Clinical Science: Concise Communication Source Type: research
CONCLUSIONS: In recent years, improvements in surgical techniques and immunosuppressive therapies have helped prolong survival of patients who undergo liver transplant. However, this also has led to a rise in the incidence of long-term complications such as de novo malignancy. These patients are more likely to develop de novo malignancy than the general population, for which chronic immunosuppression is identified as a major risk factor. Early diagnosis and treatment of de novo malignancies can help obtain better prognosis and higher survival rates in these patients. PMID: 29237362 [PubMed - as supplied by publisher]
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - Category: Transplant Surgery Authors: Tags: Exp Clin Transplant Source Type: research
ConclusionRBV‐free DAA‐combinations for the treatment of HCV‐recurrence after OLT are highly efficacious and well tolerated. Our long‐term data show that viral eradication is durable but not necessarily translated into beneficial long‐term clinical outcome.This article is protected by copyright. All rights reserved.
Source: Liver International - Category: Gastroenterology Authors: Tags: Original Article Source Type: research
A nonprofit group, the Institute for Clinical and Economic Review (ICER), recently received a three-year $13.9 million grant from the Laura and John Arnold Foundation to expand its ongoing investigative scope on drug pricing to include all new medicines and price increases on existing treatments. Up until now, ICER hasn’t had the resources to review all new medicines. The additional funding “puts us on a new trajectory,” according to Steven D. Pearson, president of ICER. “Now we’re going to be able to cover the landscape.” ICER was essentially founded with a $5.3 million grant from the...
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs
This study aimed to identify independent prognostic factors for overall survival (OS) of patients with advanced non‐small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation and receiving gefitinib as first‐line treatment in real‐world practice.Materials and Methods.We enrolled 226 patients from June 2011 to May 2013. During this period, gefitinib was the only EGFR‐tyrosine kinase inhibitor reimbursed by the Bureau of National Health Insurance of Taiwan.Results.The median progression‐free survival and median OS were 11.9 months (95% confidence interval [CI]: 9.7&ndash...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer, Chinese Edition Source Type: research
(MedPage Today) -- This week's topics include treating resistant hepatitis C infection, a new regimen for breast cancer, evolution of non-small cell lung cancer, and minocycline for MS
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Cancer | Cancer & Oncology | Health | Hepatitis | Hepatitis C | Liver | Liver Transplant | Lung Cancer | Lung Transplant | Transplants | Urology & Nephrology